Karen Firestone has bought AMLX on 5 days since Mar 2023

Karen Firestone is a corporate director and investment professional who serves on the Board of Directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), where she has been an independent director since March 2023 and is classified as both a director and 10% owner in SEC filings.( At Amylyx, she sits on the Audit Committee and the Nominating and Corporate Governance Committee, contributing financial oversight and governance expertise to the company’s leadership.( She has reported multiple purchases of Amylyx common stock via Form 4 filings, including transactions in 2024 and 2025 that have increased her equity stake in the company.(

Firestone brings more than three decades of investment and asset management experience, notably as chairman, CEO, and co‑founder of Aureus Asset Management and previously as a fund manager at Fidelity Investments, experience highlighted by Amylyx in connection with her board appointment.( Public ownership and insider-trading databases describe her as a long-term investor in Amylyx, with several buy-only transactions over the past five years and an estimated net worth substantially tied to her Amylyx holdings.( Specific details of her earlier career roles and formal education are not fully enumerated in the cited sources, but her professional profile is consistently characterized by senior leadership in asset management and extensive public‑markets expertise.(

Written by Perplexity from public sources.